GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aurinia Pharmaceuticals
Aurinia Pharmaceuticals shares are heavily dependent on the success of its only commercial drug, Lupkynis, for the treatment of lupus nephritis. The price trajectory reflects sales growth, the competitive environment, and speculation about a possible acquisition by a larger player.
Share prices of companies in the market segment - Pharma immune
Aurinia Pharmaceuticals shares are heavily dependent on the success of its sole commercial drug, Lupkynis, for the treatment of lupus nephritis. We classify the company in the Pharma-Immune sector, and the chart below reflects the dynamics of this entire segment, as well as Aurinia's sales growth history.
Broad Market Index - GURU.Markets
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases, particularly lupus nephritis. Its breakthrough drug earned it a spot on the GURU.Markets index. The chart below represents the market. See how Aurinia shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
AUPH - Daily change in the company's share price Aurinia Pharmaceuticals
Aurinia Pharmaceuticals shares exhibit high volatility, as measured by change_co. This reflects sensitivity to sales of its lupus nephritis drug and development news. This metric is important for biotech risk analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Aurinia Pharmaceuticals Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparing it to AUPH, whose success hinges on a single drug for lupus nephritis, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Aurinia is a biopharmaceutical company specializing in drugs for the treatment of autoimmune diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Aurinia's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aurinia Pharmaceuticals
Aurinia is a biopharmaceutical company specializing in the treatment of autoimmune diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough treatments.
Annual dynamics of market capitalization of the market segment - Pharma immune
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on treating autoimmune diseases. Its success depends on the commercialization of its approved drug for lupus nephritis. The chart below shows how its niche strategy and competitive environment influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aurinia Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the sales success of its drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aurinia Pharmaceuticals
Aurinia, a biopharmaceutical company whose main product is a drug for the treatment of lupus nephritis. The monthly fluctuations on the chart reflect the sales dynamics of this drug, as well as news about its potential use in other autoimmune diseases.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose lead drug is designed to treat lupus nephritis, a serious complication of an autoimmune disease. They operate in a specialized market. The chart below shows the overall dynamics in the immunology sector, where understanding and treatment options for autoimmune disorders are growing.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aurinia Pharmaceuticals already has an approved drug for the treatment of lupus nephritis on the market. Its stock price is driven by the drug's sales growth rate and the competitive environment. It's a commercialization story, where each quarterly sales report is more important than overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aurinia Pharmaceuticals
Aurinia Pharmaceuticals shares reflect the hopes of autoimmune disease patients each week. The biopharmaceutical company, whose drug is approved for the treatment of lupus nephritis, is responding to sales data and research to expand its use.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immunology-focused biotech is a sector where weekly performance is driven by clinical data. The search for new treatments for autoimmune diseases is a common trend across the board. The chart illustrates this backdrop, which can be used to assess Aurinia's commercial success and potential.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aurinia Pharmaceuticals is a biopharmaceutical company whose main product is designed to treat lupus nephritis. As a company with a single key drug, its stock can be highly volatile. The chart will show whether Aurinia is simply moving independently, responding to sales volumes, or whether the overall dynamics of the biotech sector are driving its trend.
Market capitalization of the company, segment and market as a whole
AUPH - Market capitalization of the company Aurinia Pharmaceuticals
Aurinia's market capitalization tells the story of a single-product biotech focused on treating lupus nephritis. The chart reflects the commercial success of its drug, Lupkynis, as well as ongoing speculation about a possible acquisition by a larger player. The dynamics are an assessment of both current sales and the strategic value of the asset.
AUPH - Share of the company's market capitalization Aurinia Pharmaceuticals within the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary success is a drug for the treatment of lupus nephritis, a serious complication of lupus. Its dominant market share in this niche reflects its breakthrough. The chart illustrates how successful development of a single drug can transform a small company into a significant player.
Market capitalization of the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose drug is approved for the treatment of lupus nephritis. The chart below shows the overall market capitalization of this sector. Its dynamics provide the backdrop against which Aurinia is commercializing its product, facing the challenges of bringing a drug for a rare disease to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aurinia Pharmaceuticals developed and commercialized the first drug for the treatment of lupus nephritis. Its market capitalization is based on the success of this product. The chart below shows the economic weight a company can wield when solving a single, yet important, medical problem.
Book value capitalization of the company, segment and market as a whole
AUPH - Book value capitalization of the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals' book value is its capital, supporting the commercialization of its already approved drug for lupus nephritis and the exploration of new indications. This represents a tangible, scientific, and commercial foundation. How has this asset changed since receiving FDA approval? The chart below illustrates this important transformation.
AUPH - Share of the company's book capitalization Aurinia Pharmaceuticals within the market segment - Pharma immune
Aurinia Pharmaceuticals developed and commercialized a drug for the treatment of lupus nephritis, relying on its R&D capabilities. The chart shows the share of these tangible assets in the sector, reflecting the physical foundation that enabled the company to create and commercialize this important product.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat autoimmune diseases, as the BCap_Seg chart for biotech shows, is knowledge-intensive. Aurinia Pharmaceuticals operates in this environment. Its primary asset is an approved drug and research data, not manufacturing capacity, making its business intellectually, rather than physically, capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
Aurinia Pharmaceuticals' assets are not so much its factories as the intellectual property surrounding its lupus nephritis drug. Its book value reflects the capital invested in research and the patents that protect the rights to produce this tangible and vital drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aurinia Pharmaceuticals
Aurinia Pharmaceuticals has an approved drug for the treatment of lupus nephritis. Its book value is low compared to its sales potential. The MvsBCap chart reflects the market's estimate of the drug's peak sales and the likelihood of an acquisition by a larger player. The dynamics will depend on sales reports and news.
Market to book capitalization ratio in a market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis. The company's value is closely tied to the sales success of this drug and its future development. The chart shows how the market values the commercial potential of its key asset.
Market to book capitalization ratio for the market as a whole
Aurinia Pharmaceuticals focuses on treating autoimmune diseases. Following the approval of its first drug, its market valuation reflects both current sales and potential for further research. This chart shows how investors balance actual revenues with future scientific prospects when valuing the biotech company.
Debts of the company, segment and market as a whole
AUPH - Company debts Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is using the capital to commercialize its lupus nephritis drug and for further research. Bringing a new drug to market, especially for rare diseases, requires significant marketing and distribution costs. This chart shows how the company is funding its transition from R&D to full commercialization.
Market segment debts - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases. Commercializing an approved drug and conducting new research requires significant resources. Its debt policy may reflect the transition from an R&D company to a commercial organization. The chart illustrates how Aurinia is managing this transition.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune diseases. This chart shows its financial structure. For a company whose success depends on the commercialization of a single key drug, a conservative approach to debt is a sign of prudent risk management. It provides greater financial flexibility and resilience.
Market segment debt to market segment book capitalization - Pharma immune
Aurinia Pharmaceuticals is a pharmaceutical company focused on autoimmune diseases. This metric, for the pharmaceutical industry, reflects how companies of its size finance research and the launch of new drugs. It helps assess whether the company's debt load is a result of investments in growth or operational problems.
Debt to book value of all companies in the market
Aurinia Pharmaceuticals is a pharmaceutical company. Its funding depends on sales and development success. This chart reflects the overall risk appetite in the economy. For a company in this industry, it helps understand how its funding model aligns with the overall market situation and investor confidence in its products.
P/E of the company, segment and market as a whole
P/E - Aurinia Pharmaceuticals
This chart from Aurinia Pharmaceuticals, which focuses on treating autoimmune diseases, shows market expectations for its key drug. The indicator's dynamics reflect investors' confidence in the lupus nephritis drug's sales growth and its potential to become a standard of care, which determines the company's overall future profitability.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the pharmaceutical industry, where Aurinia occupies its niche. Comparing the company's P/E to this average helps understand how the market views the commercial potential of its key lupus nephritis drug relative to other pharmaceutical assets.
P/E of the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious autoimmune disease. The company's success hinges on a single drug. This chart, reflecting overall biotech sentiment, helps understand how the market assesses the risks associated with such a concentration and the drug's potential to become a standard of care.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis. The chart reflects future revenue expectations, which depend on sales growth for this drug and its successful launch into new markets. Analysts assess whether the company will be able to maximize the potential of its key asset.
%20P%2FE%20Aurinia%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aurinia-Pharmaceuticals&v=1772682544682 "Chart of the company's future (projected) P/E Aurinia Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose lead drug is designed to treat lupus nephritis, a serious complication of systemic lupus erythematosus. The chart shows average profitability expectations for the sector. It helps understand the market's confidence in the drug's sales potential and the company's future developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772682544708 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose lead drug is designed to treat lupus nephritis, a serious complication of the autoimmune disease. The company's success depends on the commercialization of this drug. This overall market sentiment chart helps assess how investors view biotech companies with a single key product.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772682544776 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious complication of the autoimmune disease. Profit is directly dependent on the successful sales of this drug. This chart shows the financial results of a company focused on commercializing its key therapeutic advance.
Profit of companies in the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose lead drug is designed to treat lupus nephritis, a serious complication of systemic lupus erythematosus. This focus is on a niche market. This chart shows the overall profitability of the immunology sector, where the development of targeted therapies for autoimmune diseases is a key focus.
Overall market profit
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the treatment of autoimmune diseases. Its primary growth driver is the successful commercialization of an already approved drug and the development of new ones. This process is loosely linked to general economic cycles, as reflected in this chart. Demand for drugs for serious diseases remains stable in any economic phase.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious complication of systemic lupus erythematosus. Future profits depend on sales growth and the expansion of this drug's use. This chart shows analyst expectations for the commercial success of Aurinia's key product.
%20profit%20of%20the%20company%20Aurinia%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aurinia-Pharmaceuticals&v=1772682544986 "Graph of future (projected) profit of the company Aurinia Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company whose lead drug is designed to treat lupus nephritis, a serious autoimmune disease. The company's success depends on the commercialization of this drug and its expansion. This chart shows revenue projections for the immunopharmaceuticals sector, helping to assess Aurinia's market potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772682544997 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose key product is a drug for the treatment of lupus nephritis. Its revenue depends on successful sales and expansion of the drug's use. The overall economic situation, reflected in this chart, affects the solvency of the healthcare system and the affordability of expensive medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772682545023 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis. Revenue is directly dependent on the successful commercialization of this drug. This chart shows how investors assess the drug's potential peak sales and the company's ability to expand its use.
P/S market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the treatment of autoimmune diseases. Its lead commercial product is the first approved oral treatment for lupus nephritis, demonstrating its innovative potential. This chart reflects the average revenue estimate for the sector, which helps assess Aurinia's market position.
P/S of the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious autoimmune disease. The company's success depends on the commercialization of this drug. This chart helps understand how the market values biotech companies with a single key product versus diversified businesses.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious complication of systemic lupus erythematosus. Estimating future revenue is critically important for the company. It reflects investor expectations for sales growth and market penetration of this drug, which is a key driver of the company's value.
%20P%2FS%20Aurinia%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aurinia-Pharmaceuticals&v=1772682545144 "The graph of the company's future (projected) P/S Aurinia Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases. Its key product is a drug for lupus nephritis. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the commercial success of its drug and its potential for broader use.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772682545265 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Aurinia Pharmaceuticals focuses on treating autoimmune diseases. The company's success depends on a single key drug. In the overall revenue expectations pictured in the chart, Aurinia represents an example of a high-risk biotech company with high growth potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772682545601 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aurinia Pharmaceuticals
This chart shows the revenue of Aurinia Pharmaceuticals, a biopharmaceutical company whose primary revenue is generated from sales of LUPKYNIS, a drug used to treat lupus nephritis. This growth directly reflects the drug's successful commercialization, its acceptance by physicians, and expanded access for patients suffering from this autoimmune disease.
Sales of companies in the market segment - Pharma immune
Aurinia Pharmaceuticals focuses on treating autoimmune diseases. Its revenue is generated almost entirely by sales of LUPKYNIS, a drug for the treatment of lupus nephritis. The regional sales breakdown (primarily the US) reveals the company's current market and its enormous potential for future international expansion.
Overall market sales
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases. The company's success depends on the effectiveness of its drugs and regulatory approvals. This overall economic performance has little impact on demand for life-saving medications, highlighting the non-cyclical nature of advanced pharmaceuticals.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is designed to treat lupus nephritis, a serious complication of systemic lupus erythematosus. The company's revenue growth is directly dependent on the increasing number of patients using its drug. This chart shows analyst sales forecasts, reflecting their assessment of market penetration and demand growth.
%20sales%20of%20the%20company%20Aurinia%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aurinia-Pharmaceuticals&v=1772682545829 "Schedule of future (projected) sales of the company Aurinia Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the treatment of autoimmune diseases, particularly lupus nephritis. This chart shows the outlook for the immunology sector. Is the market for autoimmune disorders growing? This helps assess the overall demand for innovative treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772682545942 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose key product is a drug for the treatment of lupus nephritis. Its success depends on sales of this drug and further clinical development. The need for treatments for autoimmune diseases is independent of the economic situation, so this schedule has minimal impact on Aurinia's core business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772682545988 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases. Its key product is designed to treat lupus nephritis. This chart shows the company's success in commercializing its drug. Profitability depends on sales volume, insurance approval, and the expansion of the drug's use.
Market segment marginality - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the treatment of autoimmune diseases. Its lead product is designed to treat lupus nephritis. This metric reflects the company's financial position, whose profitability depends on successful sales of its approved drug and the competitive environment in this therapeutic area.
Market marginality as a whole
Aurinia Pharmaceuticals focuses on treating autoimmune diseases. As a biopharmaceutical company, its success depends on regulatory approval and subsequent commercialization of its drugs. This overall profitability chart reflects the state of the economy, which impacts the healthcare system's ability to pay for new, often expensive, treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is a drug for the treatment of lupus nephritis. Following FDA approval, its staff has expanded significantly to include a commercial team. This chart shows how the company is building its sales force and medical support to bring the drug to market and promote it to physicians.
Share of the company's employees Aurinia Pharmaceuticals within the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company that has developed and commercialized a drug for the treatment of lupus nephritis. The transition from R&D to sales requires expanding its staff with marketers and sales specialists. This graph shows the company's market share, and its dynamics may reflect the success of its product commercialization.
Number of employees in the market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the treatment of autoimmune diseases, particularly lupus nephritis. The growth in the immunopharmaceutical sector, as shown in the chart, highlights breakthroughs in understanding autoimmune disorders. The successful launch of a drug for a specific disease is a key growth driver for Aurinia.
Number of employees in the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company focused on treating autoimmune diseases. Its growth in clinical research and sales is directly linked to the success of its key drug. Hiring dynamics, as opposed to overall employment in this chart, is an indicator of market acceptance of a new drug.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals is a biopharmaceutical company. This chart shows the market valuation of their approved drug for lupus nephritis. The company's value is concentrated in this single product. The high market capitalization per employee reflects the monopoly position and sales potential of this drug, managed by a small team.
%20of%20the%20company%20Aurinia%20Pharmaceuticals%20(AUPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aurinia-Pharmaceuticals-AUPH&v=1772682546391 "Chart of market capitalization per employee (in thousands of dollars) of the company Aurinia Pharmaceuticals (AUPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Aurinia Pharmaceuticals (AUPH) is a biopharmaceutical company whose main product (LUPKYNIS) is designed to treat lupus nephritis (a kidney disease). This chart shows the average market capitalization per employee in the sector. It helps assess how the market views the commercial potential of their key drug and their R&D platform per employee.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772682546412 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Aurinia Pharmaceuticals is a biopharmaceutical company whose key product is designed to treat lupus nephritis. The company's value is closely tied to the success of this single drug. The chart shows how the market values the sales potential and intellectual property developed by the research team, which drives the company's high per-employee cost.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772682546473 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aurinia Pharmaceuticals (AUPH)
Aurinia is a biopharmaceutical company with an approved drug (Lupkynis) for the treatment of lupus nephritis. This chart shows how successfully the company has transitioned from R&D to commercialization. It reflects how much revenue the sales and marketing team generates from selling this highly specialized but expensive drug.
%20Chart%20Aurinia%20Pharmaceuticals%20(AUPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aurinia-Pharmaceuticals-AUPH&v=1772682546549 "Company Profit Per Employee (in thousands of dollars) Chart Aurinia Pharmaceuticals (AUPH)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Aurinia (AUPH) is an R&D biotech (the approved lupus drug Lupkynis). This chart shows the benchmark for "immune pharma" (R&D). The average profit per employee in this sector (biotech) is high. The benchmark reflects a "one-hit business": the sector spends millions on R&D, and a single successful orphan drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772682546566 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose main product (Lupkynis) is designed to treat lupus nephritis. It is a single-product company. This chart shows how successfully the company's commercial team sells this niche, expensive drug to cover R&D and marketing costs per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772682546637 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals is a biopharmaceutical company whose success depends on the commercialization of its drugs. This chart shows the financial return on their research. A high revenue per employee after product launch indicates its demand and high price, justifying years of research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aurinia-Pharmaceuticals-AUPH&v=1772682546658 "Sales chart per company employee Aurinia Pharmaceuticals (AUPH)")
Sales per employee in the market segment - Pharma immune
Aurinia Pharmaceuticals is a biotech focused on autoimmune diseases. Their flagship product is a lupus nephritis treatment (Lupkynis). This chart shows the average revenue for the sector. For AUPH, this is an indicator of commercial success: how effective is their sales and marketing team in promoting and selling this specialized drug?
Sales per employee for the market as a whole
Aurinia Pharmaceuticals is a biopharmaceutical company whose primary product is a treatment for lupus nephritis. With an approved and commercialized product, the company is in the sales growth phase. This indicator demonstrates how effectively their relatively small team (sales, R&D) is generating revenue from this niche drug.
Short shares by company, segment and market as a whole
Shares shorted by company Aurinia Pharmaceuticals (AUPH)
Aurinia (AUPH) is a biopharmaceutical company whose main product is a drug for the treatment of lupus nephritis (an autoimmune kidney disease). This chart shows the number of short positions. Short sellers may be skeptical of the drug's sales growth rate, fearful of competition, or betting that the company will be unable to expand its use.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aurinia-Pharmaceuticals-AUPH&v=1772682546729 "Short Shares Chart for the Company Aurinia Pharmaceuticals (AUPH)")
Shares shorted by market segment - Pharma immune
Aurinia Pharmaceuticals (AUPH) specializes in autoimmune diseases. Its main product is a drug for the treatment of lupus nephritis. This chart aggregates short positions in the immunopharmaceuticals sector. It reflects investor concerns about the commercial success of niche drugs or competition from large players.
Shares shorted by the overall market
Aurinia (AUPH) is a biotech focused on autoimmune diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (AUPH) is a biopharmaceutical company whose main product is Lupkynis, the first FDA-approved oral drug for lupus nephritis. Their success depends on the pace of commercialization. This chart measures momentum. It indicates "overbought" (above 70) on strong sales reports or takeover rumors, and "oversold" (below 30) on competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aurinia-Pharmaceuticals-AUPH&v=1772682546855 "RSI 14 indicator chart for the company's stock Aurinia Pharmaceuticals (AUPH)")
RSI 14 Market Segment - Pharma immune
Aurinia (AUPH) is a biotech company whose greatest success is Lupkynis, the first oral treatment for lupus nephritis. RSI_14_Seg for "Pharma immune" reveals whether the entire biotech segment is overheated. The chart helps us understand whether AUPH's performance reflects its commercial success or general hype.
RSI 14 for the overall market
Aurinia (AUPH) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AUPH (Aurinia Pharmaceuticals)
Aurinia Pharmaceuticals is a biopharmaceutical company whose drug Lupkynis is approved for the treatment of lupus nephritis (a serious complication of lupus). This chart shows the average analyst forecast. Their price targets are based on the pace of commercialization of Lupkynis, its market share, and rumors of a possible acquisition of the company.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AUPH-Aurinia-Pharmaceuticals&v=1772682547104 "A chart showing analyst consensus forecasts for the expected stock price. AUPH (Aurinia Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price AUPH (Aurinia Pharmaceuticals)
Aurinia Pharmaceuticals is a commercial biopharmaceutical company. Their key and only product is Lupkynis, the first approved oral treatment for lupus nephritis (a serious complication of lupus). This chart shows analysts' assessments of the commercial success and adoption rate of this niche drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AUPH-Aurinia-Pharmaceuticals&v=1772682547148 "A chart showing the difference between the consensus forecast and the actual stock price. AUPH (Aurinia Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Aurinia Pharmaceuticals is a biopharmaceutical company that commercialized LUPKYNIS, the first oral therapy for lupus nephritis. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe the drug will see sales growth in a competitive market.
Analysts' consensus forecast for the overall market share price
Aurinia Pharmaceuticals is a biotech company whose lead product is LUPKYNIS, the first oral drug approved by the FDA for the treatment of lupus nephritis (a kidney disorder associated with lupus). This chart shows overall market sentiment. For Aurinia, which is focused on commercializing a single drug, how these expectations impact healthcare budgets is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aurinia Pharmaceuticals
Aurinia (AUPH) is a biopharmaceutical company whose greatest success is Lupkynis, one of the first approved oral drugs for the treatment of lupus nephritis (a serious complication of lupus). This chart is a commercialization indicator, measuring how successfully their sales team is promoting the drug to rheumatologists and nephrologists in this competitive niche.
AKIMA Market Segment Index - Pharma immune
Aurinia Pharma (AUPH) is a single-product biotech (for now); the company made a breakthrough by creating the first approved oral drug (Lupkynis) for the treatment of lupus nephritis (a kidney disease). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this niche monopoly (AUPH) differentiate itself from the average pharma company?
The AKIM Index for the overall market
Aurinia is a biopharmaceutical company selling a drug (Lupkynis) for the treatment of lupus nephritis. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercial biotech story in a niche market compares to the overall economic trends affecting the healthcare sector.
